Immune checkpoint inhibition in lymphoid disease

British Journal of Haematology

Volumn 170, Issue 3, 2015, Pages 291-304

  Eyre, Toby A ^a   Collins, Graham P ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

CD274 (PD L1); Hodgkin lymphoma; nivolumab; PDCD1 (PD 1); pembrolizumab

Indexed keywords

BRENTUXIMAB VEDOTIN; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; IPILIMUMAB; LENALIDOMIDE; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; TICILIMUMAB; CTLA4 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ALLOGENEIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CHIMERA; CLASSICAL HODGKIN LYMPHOMA; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ELDERLY CARE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; LIGAND BINDING; LYMPHATIC SYSTEM TUMOR; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; METASTATIC MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TREATMENT PLANNING; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; PATHOLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNITY, CELLULAR; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84942156050     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13397     Document Type: Review

References (65)

1. Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., Wunderlich, J.R., Dudley, M.E., White, D.E. & Rosenberg, S.A. (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 114, 1537–1544.
2. Ait-Tahar, K., Damm-Welk, C., Burkhardt, B., Zimmermann, M., Klapper, W., Reiter, A., Pulford, K. & Woessmann, W. (2010) Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood, 115, 3314–3319.
3. Andorsky, D.J., Yamada, R.E., Said, J., Pinkus, G.S., Betting, D.J. & Timmerman, J.M. (2011) Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 17, 4232–4244.
4. Ansell, S.M., Hurvitz, S.A., Koenig, P.A., LaPlant, B.R., Kabat, B.F., Fernando, D., Habermann, T.M., Inwards, D.J., Verma, M., Yamada, R., Erlichman, C., Lowy, I. & Timmerman, J.M. (2009) Phase I study of Ipilimumab, an Anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell Non-Hodgkin lymphoma. Clinical Cancer Research, 15, 6446–6453.
5. Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., Schuster, S.J., Millenson, M.M., Cattry, D., Freeman, G.J., Rodig, S.J., Chapuy, B., Ligon, A.H., Zhu, L., Grosso, J.F., Kim, S.Y., Timmerman, J.M., Shipp, M.A. & Armand, P. (2014) PD-1 Blockade with Nivolumab in relapsed or refractory Hodgkin's lymphoma. New England Journal of Medicine, 372, 311–319.
6. Armand, P., Nagler, A., Weller, E.A., Devine, S.M., Avigan, D.E., Chen, Y.-B., Kaminski, M.S., Holland, H.K., Winter, J.N., Mason, J.R., Fay, J.W., Rizzieri, D.A., Hosing, C.M., Ball, E.D., Uberti, J.P., Lazarus, H.M., Mapara, M.Y., Gregory, S.A., Timmerman, J.M., Andorsky, D., Or, R., Waller, E.K., Rotem-Yehudar, R. & Gordon, L.I. (2013) Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 31, 4199–4206.
7. Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., Freeman, G.J. & Ahmed, R. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 439, 682–687.
8. Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., Lowy, I., Solomon, S.R., Morris, L.E., Holland, H.K., Mason, J.R., Alyea, E.P., Soiffer, R.J. & Ball, E.D. (2009) CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood, 113, 1581–1588.
9. Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A. & Nagler, A. (2008) Phase i safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clinical Cancer Research, 14, 3044–3051.
10. Blank, C. (2004) PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8 + T Cells. Cancer Research, 64, 1140–1145.
11. Chang, D.H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S.D., Jagannath, S. & Dhodapkar, M.V. (2006) Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood, 108, 618–621.
12. Cheson, B.D., Fisher, R.I., Barrington, S.F., Cavalli, F., Schwartz, L.H., Zucca, E. & Lister, T.A. (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification. Journal of Clinical Oncology, 32, 3059–3068.
13. Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., Roche, P.C., Lu, J., Zhu, G., Tamada, K., Lennon, V.A., Celis, E. & Chen, L. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine, 8, 793–800.
14. Egen, J.G. & Allison, J.P. (2002) Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity, 16, 23–35.
15. Evens, A.M., Sweetenham, J.W. & Horning, S.J. (2008) Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park, N.Y.), 22, 1369–1379.
16. Fanoni, D., Tavecchio, S., Recalcati, S., Balice, Y., Venegoni, L., Fiorani, R., Crosti, C. & Berti, E. (2011) New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas. Immunology Letters, 134, 157–160.
17. Fowler, N.H., Davis, R.E., Rawal, S., Nastoupil, L., Hagemeister, F.B., McLaughlin, P., Kwak, L.W., Romaguera, J.E., Fanale, M.A., Fayad, L.E., Westin, J.R., Shah, J., Orlowski, R.Z., Wang, M., Turturro, F., Oki, Y., Claret, L.C., Feng, L., Baladandayuthapani, V., Muzzafar, T., Tsai, K.Y., Samaniego, F. & Neelapu, S.S. (2014) Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. The Lancet. Oncology, 15, 1311–1318.
18. Francisco, L.M., Salinas, V.H., Brown, K.E., Vanguri, V.K., Freeman, G.J., Kuchroo, V.K. & Sharpe, A.H. (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. The Journal of Experimental Medicine, 206, 3015–3029.
19. Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L.J., Malenkovich, N., Okazaki, T., Byrne, M.C., Horton, H.F., Fouser, L., Carter, L., Ling, V., Bowman, M.R., Carreno, B.M., Collins, M., Wood, C.R. & Honjo, T. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. The Journal of Experimental Medicine, 192, 1027–1034.
20. Gavin, M.A., Rasmussen, J.P., Fontenot, J.D., Vasta, V., Manganiello, V.C., Beavo, J.A. & Rudensky, A.Y. (2007) Foxp3-dependent programme of regulatory T-cell differentiation. Nature, 445, 771–775.
21. Green, M.R., Monti, S., Rodig, S.J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T.R., Kutok, J.L. & Shipp, M.A. (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood, 116, 3268–3277.
22. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., Akerley, W., van den Eertwegh, A.J.M., Lutzky, J., Lorigan, P., Vaubel, J.M., Linette, G.P., Hogg, D., Ottensmeier, C.H., Lebbé, C., Peschel, C., Quirt, I., Clark, J.I., Wolchok, J.D., Weber, J.S., Tian, J., Yellin, M.J., Nichol, G.M., Hoos, A. & Urba, W.J. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363, 711–723.
23. Hori, S., Nomura, T. & Sakaguchi, S. (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science(New York, N.Y.), 299, 1057–1061.
24. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T. & Minato, N. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proceedings of the National Academy of Sciences of the United States of America, 99, 12293–12297.
25. Keir, M.E., Liang, S.C., Guleria, I., Latchman, Y.E., Qipo, A., Albacker, L.A., Koulmanda, M., Freeman, G.J., Sayegh, M.H. & Sharpe, A.H. (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. The Journal of Experimental Medicine, 203, 883–895.
26. Keir, M.E., Butte, M.J., Freeman, G.J. & Sharpe, A.H. (2008) PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology, 26, 677–704.
27. Klimm, B., Diehl, V. & Engert, A. (2007) Hodgkin's lymphoma in the elderly: a different disease in patients over 60. Oncology (Williston Park, N.Y.), 21, 982–990; discussion 990, 996, 998 passim.
28. Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H. & Nishimura, M. (2004) B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 10, 5094–5100.
29. Latchman, Y., Wood, C.R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A.J., Brown, J.A., Nunes, R., Greenfield, E.A., Bourque, K., Boussiotis, V.A., Carter, L.L., Carreno, B.M., Malenkovich, N., Nishimura, H., Okazaki, T., Honjo, T., Sharpe, A.H. & Freeman, G.J. (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology, 2, 261–268.
30. Leach, D.R., Krummel, M.F. & Allison, J.P. (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science (New York, N.Y.), 271, 1734–1736.
31. Lenschow, D.J., Walunas, T.L. & Bluestone, J.A. (1996) CD28/B7 system of T cell costimulation. Annual Review of Immunology, 14, 233–258.
32. Lesokhin, A.M., Ansell, S.M., Armand, P., Scott, E.C., Halwani, A., Gutierrez, M., Millenson, M.M., Cohen, A.D., Schuster, S.J., Lebovic, D., Dhodapkar, M.V., Avigan, D., Chapuy, B., Ligon, A.H., Rodig, S.J., Cattry, D., Zhu, L., Grosso, J.F., Kim, S.Y., Shipp, M.A., Borrello, I. & Timmerman, J. (2014) Preliminary results of a phase I study of Nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood, 124, 291.
33. Li, Y., Wang, J., Li, C. & Ke, X.-Y. (2012) Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leukemia & Lymphoma, 53, 2015–2023.
34. Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L.S., Damle, N.K. & Ledbetter, J.A. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. The Journal of Experimental Medicine, 174, 561–569.
35. Linsley, P.S., Greene, J.L., Brady, W., Bajorath, J., Ledbetter, J.A. & Peach, R. (1994) Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity, 1, 793–801.
36. Luptakova, K., Rosenblatt, J., Glotzbecker, B., Mills, H., Stroopinsky, D., Kufe, T., Vasir, B., Arnason, J., Tzachanis, D., Zwicker, J.I., Joyce, R.M., Levine, J.D., Anderson, K.C., Kufe, D. & Avigan, D. (2013) Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunology, Immunotherapy, 62, 39–49.
37. Marzec, M., Zhang, Q., Goradia, A., Raghunath, P.N., Liu, X., Paessler, M., Wang, H.Y., Wysocka, M., Cheng, M., Ruggeri, B.A. & Wasik, M.A. (2008) Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proceedings of the National Academy of Sciences of the United States of America, 105, 20852–20857.
38. Moskowitz, C.H., Ribrag, V., Michot, J.-M., Martinelli, G., Zinzani, P.L., Gutierrez, M., Maeyer, G., De Jacob, A.G., Giallella, K., Anderson, J.W., Derosier, M., Wang, J., Yang, Z., Rubin, E., Rose, S., Shipp, M.A. & Armand, P. (2014) PD-1 blockade with the monoclonal antibody Pembrolizumab (MK-3475) in patients with classical hodgkin lymphoma after Brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). Blood, 124, 290.
39. Muraro, E., Martorelli, D. & Dolcetti, R. (2013) Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas. Human Vaccines & Immunotherapeutics, 9, 1078–1083.
40. Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 11, 141–151.
41. Pardoll, D.M. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12, 252–264.
42. Peggs, K.S., Sureda, A., Qian, W., Caballero, D., Hunter, A., Urbano-Ispizua, A., Cavet, J., Ribera, J.M., Parker, A., Canales, M., Mahendra, P., Garcia-Conde, J., Milligan, D., Sanz, G., Thomson, K., Arranz, R., Goldstone, A.H., Alvarez, I., Linch, D.C., Sierra, J., Mackinnon, S. & UK and Spanish Collaborative Groups. (2007) Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. British Journal of Haematology, 139, 70–80.
43. Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J. & Allison, J.P. (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. The Journal of Experimental Medicine, 206, 1717–1725.
44. Pulford, K., Lamant, L., Morris, S.W., Butler, L.H., Wood, K.M., Stroud, D., Delsol, G. & Mason, D.Y. (1997) Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood, 89, 1394–1404.
45. Pulford, K., Falini, B., Banham, A.H., Codrington, D., Roberton, H., Hatton, C. & Mason, D.Y. (2000) Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood, 96, 1605–1607.
46. Qureshi, O.S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E.M., Baker, J., Jeffery, L.E., Kaur, S., Briggs, Z., Hou, T.Z., Futter, C.E., Anderson, G., Walker, L.S.K. & Sansom, D.M. (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science(New York, N.Y.), 332, 600–603.
47. Ramsay, A.G., Clear, A.J., Kelly, G., Fatah, R., Matthews, J., MacDougall, F., Lister, T.A., Lee, A.M., Calaminici, M. & Gribben, J.G. (2009) Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood, 114, 4713–4720.
48. Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, W.H., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., Francis, S., Chen, T.T., Humphrey, R., Hoos, A. & Wolchok, J.D. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364, 2517–2526.
49. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K.J., Hernberg, M.M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Arance, A., Schmidt, H., Schadendorf, D., Gogas, H., Lundgren-Eriksson, L., Horak, C., Sharkey, B., Waxman, I.M., Atkinson, V. & Ascierto, P.A. (2015) Nivolumab in previously untreated melanoma without BRAF mutation. New England Journal of Medicine, 372, 320–330.
50. Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R.D., Chan, W.C., Zhao, T., Haioun, C., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Campo, E., Montserrat, E., Lopez-Guillermo, A., Ott, G., Muller-Hermelink, H.K., Connors, J.M., Braziel, R., Grogan, T.M., Fisher, R.I., Miller, T.P., LeBlanc, M., Chiorazzi, M., Zhao, H., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D. & Staudt, L.M. (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. The Journal of Experimental Medicine, 198, 851–862.
51. Rudd, C.E., Taylor, A. & Schneider, H. (2009) CD28 and CTLA-4 coreceptor expression and signal transduction. Immunological Reviews, 229, 12–26.
52. Sfanos, K.S., Bruno, T.C., Meeker, A.K., De Marzo, A.M., Isaacs, W.B. & Drake, C.G. (2009) Human prostate-infiltrating CD8 + T lymphocytes are oligoclonal and PD-1 + . Prostate, 69, 1694–1703.
53. Shin, T., Yoshimura, K., Shin, T., Crafton, E.B., Tsuchiya, H., Housseau, F., Koseki, H., Schulick, R.D., Chen, L. & Pardoll, D.M. (2005) In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. The Journal of Experimental Medicine, 201, 1531–1541.
54. Steidl, C., Shah, S.P., Woolcock, B.W., Rui, L., Kawahara, M., Farinha, P., Johnson, N.A., Zhao, Y., Telenius, A., Neriah, S.Ben, McPherson, A., Meissner, B., Okoye, U.C., Diepstra, A., van den Berg, A., Sun, M., Leung, G., Jones, S.J., Connors, J.M., Huntsman, D.G., Savage, K.J., Rimsza, L.M., Horsman, D.E., Staudt, L.M., Steidl, U., Marra, M.A. & Gascoyne, R.D. (2011) MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature, 471, 377–381.
55. Taube, J.M., Anders, R.A., Young, G.D., Xu, H., Sharma, R., McMiller, T.L., Chen, S., Klein, A.P., Pardoll, D.M., Topalian, S.L. & Chen, L. (2012) Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Science Translational Medicine, 4, 127ra37–127ra37.
56. Terasawa, T., Lau, J., Bardet, S., Couturier, O., Hotta, T., Hutchings, M., Nihashi, T. & Nagai, H. (2009) Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. Journal of Clinical Oncology, 27, 1906–1914.
57. Tivol, E.A., Borriello, F., Schweitzer, A.N., Lynch, W.P., Bluestone, J.A. & Sharpe, A.H. (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3, 541–547.
58. Tseng, S.-Y., Otsuji, M., Gorski, K., Huang, X., Slansky, J.E., Pai, S.I., Shalabi, A., Shin, T., Pardoll, D.M. & Tsuchiya, H. (2001) B7-Dc, a new dendritic cell molecule with potent costimulatory properties for T Cells. Journal of Experimental Medicine, 193, 839–846.
59. Van Elsas, A., Hurwitz, A.A. & Allison, J.P. (1999) Combination immunotherapy of B16 Melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (Ctla-4) and Granulocyte/macrophage colony-stimulating factor (Gm-Csf)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied. Journal of Experimental Medicine, 190, 355–366.
60. Waterhouse, P., Penninger, J.M., Timms, E., Wakeham, A., Shahinian, A., Lee, K.P., Thompson, C.B., Griesser, H. & Mak, T.W. (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science(New York, N.Y.), 270, 985–988.
61. Westin, J.R., Chu, F., Zhang, M., Fayad, L.E., Kwak, L.W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., Feng, L., Baladandayuthapani, V., Wang, Z., Ma, W., Gao, Y., Wallace, M., Vence, L.M., Radvanyi, L., Muzzafar, T., Rotem-Yehudar, R., Davis, R.E. & Neelapu, S.S. (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. The Lancet. Oncology, 15, 69–77.
62. Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T. & Sakaguchi, S. (2008) CTLA-4 control over Foxp3 + regulatory T cell function. Science (New York, N.Y.), 322, 271–275.
63. Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M. A, Rizvi, N. A, Lesokhin, A.M., Segal, N.H., Ariyan, C.E., Gordon, R.-A., Reed, K., Burke, M.M., Caldwell, A., Kronenberg, S. A, Agunwamba, B.U., Zhang, X., Lowy, I., Inzunza, H.D., Feely, W., Horak, C.E., Hong, Q., Korman, A.J., Wigginton, J.M., Gupta, A. & Sznol, M. (2013) Nivolumab plus ipilimumab in advanced melanoma. The New England Journal of Medicine, 369, 122–133.
64. Zhou, J., Bashey, A., Zhong, R., Corringham, S., Messer, K., Pu, M., Ma, W., Chut, T., Soiffer, R., Mitrovich, R.C., Lowy, I. & Ball, E.D. (2011) CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 17, 682–692.
65. Zou, W. & Chen, L. (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews. Immunology, 8, 467–477.